Cetuximab or Nimotuzumab Versus Cisplatin Concurrent with Radiotherapy for Local-Regionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis

BACKGROUND: It is unclear whether Cetuximab (CTX) or Nimotuzumab (NTZ) concurrent with radiotherapy delivers equivalent or improved results with fewer toxicities over standard cisplatin (CDDP) concurrent with radiotherapy in locally advanced nasopharyngeal carcinoma (NPC). METHODS: The strategy invo...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhong Guo, Lin, Guo Xiang, Ye, Jia Xiang, Li, Ye, Li, Ling, Qu, Song, Liang, Xia, Zhu, Xiao Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031838/
https://www.ncbi.nlm.nih.gov/pubmed/29802706
http://dx.doi.org/10.22034/APJCP.2018.19.5.1397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031838/
https://www.ncbi.nlm.nih.gov/pubmed/29802706
http://dx.doi.org/10.22034/APJCP.2018.19.5.1397

Ejemplares similares